Arvinas ARVN Business Segments
| FY'25 | FY'24 | FY'23 | ||
|---|---|---|---|---|
| Program-specific external expense by Product | ||||
| ARV-102 | $21M+61.5% | $13M+465% | $2.3M— | |
| ARV-393 | $11.1M+63.2% | $6.8M+386% | $1.4M— | |
| ARV-806 | $13.5M+487% | $2.3M— | $0— | |
| Bavdegalutamide (ARV-110) | $2.7M-68.2% | $8.5M-68.0% | $26.6M— | |
| Other programs | $4.5M+4,400% | $100K— | $0-100% | |
| Vepdegestrant ARV-471 | $62.7M-18.5% | $76.9M-26.6% | $104.8M— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Arvinas break its business down?
- Arvinas (ARVN) reports program-specific external expense by product across 6 parts — ARV-102, ARV-393, ARV-806, Bavdegalutamide (ARV-110) and Other programs. Each is extracted from the segment footnotes and tracked over time.
- Where does Arvinas's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Arvinas's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
